ME 401

Drug Profile

ME 401

Alternative Names: Kinase program - MEI Pharma; ME401; PWT-143

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pathway Therapeutics
  • Developer MEI Pharma
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies

Most Recent Events

  • 31 May 2017 Safety data from a phase Ib trial in Chronic lymphocytic leukaemia and Follicular lymphoma released by MEI Pharma
  • 24 Feb 2017 MEI Pharma completes a phase I trial in Haematological malignancies in the UK (NCT02521389)
  • 01 Sep 2016 Phase-I clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (unspecified route) (NCT02914938)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top